Elizabeth M. Hill

State of the science in smoldering myeloma: Should we be treating in the clinic?

D. Kazandjian, E. Hill, Alexander Dew, 2019, Seminars in oncology.

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

E. Papaemmanuil, I. Maric, O. Landgren, 2019, Blood Cancer Journal.

The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!

D. Kazandjian, E. Hill, Alexander Dew, 2020, Best practice & research. Clinical haematology.

Genomic Profiling to Contextualize the Results of Intervention for High-Risk Smoldering Myeloma

I. Ghobrial, F. Davies, G. Getz, 2023, medRxiv.

Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

S. Steinberg, K. Camphausen, P. Choyke, 2021, The oncologist.

Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients

Neha Korde, Venkata Yellapantula, Elli Papaemmanuil, 2019, Blood Cancer Journal.